Question 1

Does RoukenBio service the United States?

Accepted Answer

As a global pharmaceutical contract research organization, RoukenBio provides drug development services to the vast scientific network worldwide. Our scientific partners are based mainly in the USA—particularly in Massachusetts (Boston, Cambridge) and California (San Francisco and San Diego)—Canada (from Vancouver up to Seattle), the UK, and Europe.

Question 2

How does RoukenBio tailor its assay solutions for different therapeutic modalities?

Accepted Answer

As a Drug Discovery CRO with special focus on developing bespoke assay solutions and innovative methods toward unique drug development needs, we tailor solutions to various therapeutic modalities covering immunology, immune-oncology, autoimmune disease, inflammation, allergy and more.

The type of molecules our cross-functional teams work with are diverse. We cover all immunotherapy and antibody-based molecules and therapeutic modalities like;

Monoclonal antibodies (mAbs)
Bispecific antibodies (BsAbs)
Multi-specifics, multispecific molecules
Immunocytokines, antibody-cytokine fusion proteins
Cell therapies
Targeted protein degraders (TPDs)
Small molecules
Large molecules
Oligonucleotide-based nanoparticles
Complex biologics
Peptides and more

Our assay platforms, methodologies and custom solutions have been applied to all the drug classes listed above and the list is constantly growing.

Question 3

What makes RoukenBio’s approach unique to supporting large molecules?

Accepted Answer

RoukenBio’s approach to supporting large molecules is unique due to its comprehensive and customizable services spanning the entire development process, from early discovery to pre-IND testing.

Our expertise includes advanced characterization, optimization, and in-depth scientific knowledge, especially in cell line engineering and SPR technologies. We offer integrated, bespoke services to understand function, validate mechanisms, and ensure the safety and efficacy of therapeutics like monoclonal antibodies, antibody-drug conjugates, and more.

Our innovative in vitro assays coupled with the trademarked IndEx-2 system, are crucial in assessing therapeutic interactions. We focus on disease modeling, target validation, and immune cell assays in large molecule drug development to help your therapeutic reach the clinic.

Question 4

What makes RoukenBio’s approach unique in supporting small molecules?

Accepted Answer

RoukenBio’s approach to supporting small molecules stands out due to its specialized capabilities across key stages of drug development. Our expertise in target validation, using advanced technologies like IndEx-2 and LocIn, ensures rigorous testing of therapeutic targets.

Our Biophysics team excels in binding characterization with Surface Plasmon Resonance (SPR), particularly for complex molecules or using single-cell interaction cytometry (sc-IC) to measure binding activity of therapeutic molecules while interacting with cell targets directly within their native cellular environment.

Our brilliant minds take biology assay development to the next level with method development included, creating reliable systems optimized for high-throughput screening.

With deep knowledge in disease modeling, we use patient-derived material to replicate clinical conditions, ensuring that therapeutic candidates are tested in the most relevant biological settings.

Additionally, we focus on immunotoxicology that helps assess risks, such as cytokine release syndrome, ensuring safety is assessed before clinical trials.

This fully comprehensive, innovative approach accelerates small molecule development from discovery to clinical success all under the same roof, in our Rouken Discovery Centre.

Question 5

What makes RoukenBio’s approach unique in supporting cell therapies?

Accepted Answer

With a world-class cell engineering and molecular biology team on board, we specialize in immune cell therapies, offering expertise in construct design and cell engineering covering CAR-T, TCR-T, CAR-NK, CAR-γδ T, and CAR-Macrophages.

Our advanced technologies, including cutting-edge gene editing tools, enable precise cell modification. We pay special attention to safety with in-depth preclinical testing, assessing risks such as cytokine release syndrome and on-target off-tumour toxicity.

At RoukenBio, we advocate efficacy testing, using innovative 3D model assays and advanced in vitro tumour microenvironment models to ensure optimal therapeutic outcomes. With robust safety profiles, comprehensive characterization, and a deep understanding of primary immune cell biology, we ensure the development of effective and safe cell therapies.

Question 6

Can RoukenBio assist with both early-stage discovery and clinical development for different modalities?

Accepted Answer

RoukenBio can assist with early-stage discovery to pre-IND testing of various modalities, including large molecules, small molecules, and cell therapies. We aid biotherapeutic innovators and drug developers with our bespoke in vitro assay solutions and expert cross-functional support throughout the entire drug development process, from discovery to pre-IND testing.

Therapeutic Antibody Development and Modalities

Modalities We Support

Explore how we support your modality:

Large Molecules

Cell Therapy

Small Molecules

Propel drug discovery breakthroughs with RoukenBio

FAQs